Comparative Efficacy of Subcutaneous Versus Intravenous Interleukin 12/23 Inhibitors for the Remission of Moderate to Severe Crohn’s Disease: A Systematic Review and Meta-Analysis

Comparative Efficacy of Subcutaneous Versus Intravenous Interleukin 12/23 Inhibitors for the Remission of Moderate to Severe Crohn’s Disease: A Systematic Review and Meta-Analysis

<b>Background/Objectives</b>: Interleukin 12/23 inhibitors are a newer class of monoclonal antibodies used to induce and maintain remission for Crohn’s disease (CD), a chronic inflammatory bowel disease, when patients do not respond to conventional immunomodulatory drugs or first-line mo...

Full description

Saved in:
Bibliographic Details
Main Authors: Nouran Alwisi, Rana Ismail, Hissa Al-Kuwari, Khalifa H. Al-Ansari, Mohammed A. Al-Matwi, Noor A. Aweer, Wejdan N. Al-Marri, Yousif Al-Kubaisi, Muneera Al-Mohannadi, Shahd Hamran, Suhail A. R. Doi, Habib H. Farooqui, Tawanda Chivese
Format: Article
Language:English
Published: MDPI AG 2025-03-01
Series:Biomedicines
Subjects:
Crohn’s disease (CD)
interleukin inhibitors
monoclonal antibodies (mAbs)
subcutaneous (SC)
intravenous (IV)
meta-analysis
Online Access:https://www.mdpi.com/2227-9059/13/3/702
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items